Kutti J, Bergström A L, Ridell B
Acta Med Scand. 1982;211(4):301-4. doi: 10.1111/j.0954-6820.1982.tb01949.x.
The megakaryocyte number and mean megakaryocyte area were determined in histological sections of sternal bone marrow from 26 patients with systemic lupus erythematosus (SLE). Also 20 platelet survival studies were carried out in these patients. The results were analyzed with respect to corticosteroid (CS) and CS + azathioprine (AT) therapy. The mean bone marrow megakaryocyte number as highest in untreated SLE patients, slightly lower in patients receiving CSs and lowest in those receiving CSs + AT. The difference was, however, not significant. The mean megakaryocyte areas were smallest in untreated SLE patients, slightly larger in those treated with CSs and significantly (p less than 0.05) larger in patients who received CSs + AT than in untreated patients. Platelet production rate was normal in all 3 groups of SLE patients. The results suggest that CS and AT therapy in SLE intervenes with the bone marrow megakaryopoiesis without affecting the production rate of platelets.
测定了26例系统性红斑狼疮(SLE)患者胸骨骨髓组织切片中的巨核细胞数量和平均巨核细胞面积。此外,还对这些患者进行了20项血小板存活研究。对皮质类固醇(CS)和CS +硫唑嘌呤(AT)治疗的结果进行了分析。未治疗的SLE患者骨髓巨核细胞平均数量最高,接受CS治疗的患者略低,接受CS + AT治疗的患者最低。然而,差异不显著。未治疗的SLE患者平均巨核细胞面积最小,接受CS治疗的患者略大,接受CS + AT治疗的患者比未治疗的患者显著更大(p < 0.05)。所有3组SLE患者的血小板生成率均正常。结果表明,SLE患者的CS和AT治疗会干扰骨髓巨核细胞生成,但不影响血小板的生成率。